# Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G/GEJC

> **NCT07273981** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Xijing Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Gastric/Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** Zanidatamab Combined with Chemotherapy

## Key facts

- **NCT ID:** NCT07273981
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-07-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07273981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07273981, "Zanidatamab Combined With Chemotherapy as Neoadjuvant Therapy for HER2-high Expression G/GEJC". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07273981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*